When Lonza announced its partnership with RION in September 2025 to manufacture platelet-derived exosome therapeutics, the collaboration signaled growing CDMO investment in specialized modalities. As exosome-based therapies advance from academic research toward commercial reality, manufacturing scale-up presents distinct technical and
The pharma manufacturing landscape in 2026 is more volatile than ever. Take part in this benchmarking study to see how your peers are responding. Rapidly changing geopolitics. Capacity constraints. Pricing pressure. Technology disruption. The challenges facing biopharma sponsors and CDMO
The 2026 J.P. Morgan Healthcare Conference revealed a shift in global pharmaceutical power dynamics, with China’s biotech sector commanding ever increasing attention from Western investors and executives who acknowledged the region’s transformation from manufacturing hub to innovation leader. You Cannot
Alliance for Regenerative Medicine’s State of the Industry briefing at JP Morgan Healthcare Conference signals cautious optimism backed by $11.1B in 2025 funding The cell and gene therapy (CGT) sector attracted $11.1 billion in investment across 216 financings in 2025—representing
‘We Created the Scene for Everyone Else’ Novo Nordisk CEO Maziar Mike Doustdar delivered a candid assessment of his company’s competitive position at the J.P. Morgan Healthcare Conference, characterizing the Danish drugmaker’s pioneering role in obesity treatment as both a
Richard Pazdur, MD, the longtime FDA drug regulator who abruptly left the agency in December, used his first public appearance at the J.P. Morgan Healthcare Conference this week to deliver a warning: the pharmaceutical industry is not taking concerns about
Guest Editorial by Audrey Greenberg, Venture Partner and Chair, Department of Business Development, Mayo Clinic Radiopharmaceuticals are accelerating clinically, but manufacturing infrastructure has not kept pace. Radioligand therapeutics exemplify the shift toward highly targeted therapeutics with outsized therapeutic impact, yet
Guest Editorial by Molly McGaughan, Co-founder and Managing Director, Firm Contract development and manufacturing organizations sit much closer to the patient experience than most people realize. Their decisions shape whether a dose arrives on time, whether rescheduling is possible, and
Guest Editorial by Clair Martin, Senior Engagement Manager, and Adam Siebert, Managing Director, LEK Consulting In radiopharmaceutical manufacturing, the real challenge is whether stated capacity can actually deliver reliable, end-to-end supply to patients under the tight timing constraints imposed by
As the pharmaceutical industry enters 2026, manufacturing leaders face a complex landscape shaped by geopolitical uncertainty, capacity constraints, and evolving therapeutic modalities. We asked senior executives across the sector what they see ahead—and their predictions reveal an industry bracing for
